SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

BioTime, Inc. (BTX)

BTX RSS Feed
Add BTX Price Alert      Hide Sticky   Hide Intro
Moderator: ahab333
Search This Board: 
Last Post: 12/6/2017 1:13:45 PM - Followers: 70 - Board type: Free - Posts Today: 0

 

BioTime, Inc.  (BTX)

 

 
 

 

http://www.biotimeinc.com/

 

 

 

Company Information:

BioTime, Inc.
1301 Harbor Bay Parkway
Alameda, CA 94502

Phone: 510-521-3390
      Fax: 510-521-3389

 

CIK

0000876343

 

 

BioTime, Inc. (NYSE AMEX: BTX) is a biotechnology company engaged in two areas of biomedical research and product development:

  • Stem cell technology and products for use in regenerative medicine.  These products and technologies are being developed and marketed by our wholly owned subsidiary Embryome Sciences, Inc.
  • Blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications.  Our lead product is Hextend® which is being marketed by Hospira, Inc. and CJ CheilJedang Corp. under exclusive licenses from us

 

The Potential of Regenerative Medicine

Regenerative medicine refers to therapies based on human embryonic stem ("hES") cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The great scientific and public interest in regenerative medicine lies in the potential of hES cells to transform into any cell type of the human body. hES cells therefore show considerable potential as a source of new therapies for a host of currently-incurable diseases such as: diabetes, stroke, Alzheimer's and Parkinson's disease, heart failure, arthritis, muscular dystrophy, spinal cord injury, macular degeneration, hearing loss, kidney and liver failure, as well as many other disorders that may be treated by replacing diseased or damaged organ tissues. In response to the unusual potential of the field, the State of California has allocated $3 billion over the next 10 years to fund basic research, and President Obama has lifted previous restrictions for federal funding of stem cell research.

Led by Dr. Michael West, considered by many to be a founding father of the stem cell industry, BioTime has assembled an array of products and associated intellectual property that give it the potential to be a leader in this exciting new field of medicine.

We are implementing a near-term revenues strategy in the regenerative medicine field by seeking to develop and market advanced hES products and technology that can be used by researchers at universities and biopharmaceutical companies. These research-only products generally can be marketed without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to human therapeutic products. We may also initiate development programs for human therapeutic applications if sufficient capital becomes available to us or through joint efforts with industry partners.

BioTime is leveraging its product development strategy on two key technology platforms:
 

  • • An advanced iPS technology allowing the transformation of human cells of the body back to a primordial stem cell state equivalent to embryonic stem cells. Using this technology with patient specific stem cells, rather than stem cells derived from embryos donated by unrelated people, may reduce the incidence of rejection of tissue grafts.
     
  • ACTCellerate™ technology that permits the generation of scalable and highly purified cells of the human body.

See this link for more information:  http://www.biotimeinc.com/aboutBT.htm

 

 

 

 

 

 

Management: 

http://www.biotimeinc.com/management.htm
 

 

Dr. Michael West, CEO

Dr. West is the Chief Executive Officer of BioTime, Inc. (NYSE AMEX: BTIM) and Embryome Sciences, Inc. of Alameda, California. The Companies are focused on developing an array of research and therapeutic products using human embryonic stem cell technology. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging. He has focused his academic and business career on the application of developmental biology to the age-related degenerative disease. He was the Founder of Geron Corporation of Menlo Park, California (Nasdaq: GERN) and from 1990 to 1998 he was a Director, and Vice President, where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells. From 1995 to 1998 he organized and managed the research collaboration between Geron and its academic collaborators James Thomson and John Gearhart that led to the first isolation of human embryonic stem and human embryonic germ cells. From 1998 to 2007 he was President and Chief Scientific Officer at Advanced Cell Technology, Inc. (OTCBB: ACTC) where he managed programs in animal cloning, human somatic cell nuclear transfer, retinal differentiation, and ACTCellerate, a technology for the multiplex derivation and characterization of clonal human embryonic progenitor cell lines. 

Dr. West's complete CV and background on his research interests are available online at: http://www.michaelwest.org/


 

 

 

 

Recent News: 

http://www.b2i.us/profiles/investor/ResLibrary2.asp?BzID=1152&GoTopage=&Category=1802&t=
 

 

http://finance.yahoo.com/q/h?s=BTX+Headlines

 

Subsidiaries
http://www.biotimeinc.com/subsidiaries/


 

 

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0000876343&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

 

 

Transfer Agent:

American Stock Transfer & Trust Company
59 Maiden Lane
New York 10038

 

Investor Relations:

Judith Segall

VP of Administration, Corporate Secretary

isegall@biotimemail.com

Phone:  510.521.3390 ext 301

 

 

 


 

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

Also, keep in mind that moderators may or may not have a position in said stock.   Being a moderator isn't a sign of endorsement.

  

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:
http://investorshub.advfn.com/boards/complex_terms.asp

 

SureTrader
Interactive Brokers Advertisement
BTX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BTX News: Confidential Treatment Order (ct Order) 12/14/2017 03:22:07 PM
BTX News: Current Report Filing (8-k) 12/11/2017 06:06:43 AM
BTX News: Additional Renevia Data From the Successful Pivotal Trial Was Presented at the IFATS Conference 12/04/2017 08:00:00 AM
BTX News: AgeX Therapeutics CEO Michael D. West to Participate in Roundtable Panel on the Path Forward for Stem Cell Therapy at Termis ... 12/04/2017 07:00:00 AM
BTX News: Data from BioTime’s Renevia® Program to Be Presented at IFATS Conference 11/30/2017 07:00:00 AM
PostSubject
#768   New slides BioTime (BTX) Presents At The 10th Annual DeepDive 12/06/17 01:13:45 PM
#767   Round table panel on the path going forward ahab333 12/04/17 01:44:01 PM
#766   I am very curious to see how they terry hallinan 12/01/17 10:46:29 AM
#765   Very true DeepDive. Bio time has so ahab333 12/01/17 10:29:33 AM
#764   Thanks Ahab. I am very curious to see how DeepDive 12/01/17 06:10:17 AM
#763   Renevia program to be presented today in Europe: ahab333 11/30/17 11:49:21 AM
#762   I was thinking how great and liberating this terry hallinan 11/27/17 08:00:06 PM
#761   I don’t quite follow the rant, but I DeepDive 11/27/17 02:27:55 PM
#760   And so,DeepDive, we will turn to ridding the terry hallinan 11/26/17 12:42:35 PM
#759   "Eggs from Skin Cells? Here’s Why the Next DeepDive 11/26/17 06:59:47 AM
#758   Since we hit 2.19 recently, BTX has been ahab333 11/24/17 11:50:56 AM
#757   I have always stated that BTX and terry hallinan 11/21/17 09:22:43 AM
#756   Terry asked: DeepDive 11/21/17 09:02:13 AM
#755   I tend to agree with most of your DeepDive 11/21/17 08:50:59 AM
#754   I fail to see how OpRegen can be terry hallinan 11/21/17 04:16:43 AM
#753   I fail to see how OpRegen can be Cincinnatus 11/20/17 11:11:18 AM
#752   OpRegen is the nearest catalyst and has incredible terry hallinan 11/20/17 09:32:26 AM
#751   "Why is that dreamy OpRegan stuff that only DeepDive 11/20/17 09:03:42 AM
#750   BTX Sub Asterias Highlights (Conf Call). DeepDive 11/20/17 08:55:48 AM
#749   The market sure didn't like the delay nor DeepDive 11/20/17 08:11:53 AM
#748   About Biotime's spin-off (and holding) Oncocyte's DetermaVu delay DeepDive 11/20/17 07:57:19 AM
#747   Why is that dreamy OpRegan stuff that only terry hallinan 11/19/17 06:33:22 AM
#746   11/14/17 OCX CC Highlights Cincinnatus 11/15/17 10:09:18 AM
#745   Brief summary of highlights of AST Cincinnatus 11/15/17 09:50:05 AM
#744   News out on Opbegen's phase I/IIa trial: ahab333 11/15/17 09:44:30 AM
#743   this is a sleeping giant in the making terry hallinan 11/13/17 02:11:26 PM
#742   Nice conversations going on here from Cincinnatus, Terry ahab333 11/13/17 11:28:01 AM
#741   BTX is not just a pretty face. terry hallinan 11/13/17 08:46:13 AM
#740   I'm way more interested in revenues and the terry hallinan 11/12/17 09:56:36 PM
#739   I'm way more interested in revenues and the Cincinnatus 11/12/17 08:38:50 PM
#738   "What is the pathway in the U.S. or terry hallinan 11/12/17 12:53:54 PM
#737   I agree with most of what you said. Cincinnatus 11/12/17 12:36:18 PM
#736   "Please, Cincinnatus, don't take umbrage at my extravagant Cincinnatus 11/12/17 11:43:33 AM
#735   Unlike what another poster wrote, the company does DeepDive 11/12/17 09:57:45 AM
#734   going after the aesthetics market would seem to terry hallinan 11/12/17 04:17:23 AM
#733   Wondering? If Premvia in U.S. is the same as Cincinnatus 11/10/17 12:23:34 PM
#732   NEWS OUT on earnings for BTX late yesterday. ahab333 11/10/17 11:29:38 AM
#731   Looking at BTX chart, it sure looks like ahab333 11/09/17 10:02:41 AM
#730   Pin this! One Flap 10/25/17 06:23:32 PM
#729   Wow, haven't seen share price down here in ahab333 10/25/17 11:47:57 AM
#728   "I am encouraged by the results seen in terry hallinan 10/16/17 12:18:28 PM
#727   New trial: Additional indications for #Revevia starting. Title: BioTime DeepDive 10/12/17 07:57:37 AM
#726   $AgeX’s Aubrey de Grey. Ok, Ok... He does DeepDive 10/10/17 03:37:27 AM
#725   It’s called “Time Arbitrage”. Short the near term return, DeepDive 10/10/17 12:14:44 AM
#724   Adi, techxen, DeepDive, you are all absolutely correct ahab333 10/09/17 02:22:06 PM
#723   Adi, all of your points are spot on techxen 10/07/17 05:53:38 PM
#722   Here are couple of facts to take into DeepDive 10/07/17 04:05:06 PM
#721   Adi, I have been looking at this stock techxen 10/07/17 09:25:04 AM
#720   Sorry, not too many traders around here. I DeepDive 10/05/17 05:34:00 AM
#719   That could be the case. What draws me to DeepDive 10/05/17 05:31:47 AM
PostSubject